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Virus neutralizationTo improve a previously constructed broadly neutralizing hepatitis B virus (HBV)-speciﬁc preS1
humanized antibody (HzKR127), we further humanized it through speciﬁcity-determining residue
(SDR) grafting. Moreover, we improved afﬁnity by mutating two residues in heavy-chain comple-
mentarity-determining regions (CDR), on the basis of the crystal structure of the antigen–antibody
complex. HzKR127-3.2 exhibited 2.5-fold higher afﬁnity and enhanced virus-neutralizing activity
compared to the original KR127 antibody and showed less immunogenic potential than HzKR127.
Enhanced virus-neutralizing activity was achieved by the increased association rate, providing
insights into engineering potent antibody therapeutics for HBV immunoprophylaxis. HzKR127-3.2
may be a good candidate for HBV immunoprophylaxis.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction residues that inﬂuence antigen-binding activity [6,7]. TheseOver the last three decades, monoclonal antibodies (mAbs) have
emerged as powerful human therapeutics due to advances in anti-
body engineering technologies [1]. Non-human antibodies induce
an immune response in humans, which limits their therapeutic
use [2]. To overcome this problem, humanized antibodies have
been constructed by grafting the complementarity-determining
regions (CDRs) of murine mAbs onto human framework regions
(FRs), which is commonly referred to as CDR grafting [3]. Simple
grafting of CDRs, however, often decreases afﬁnity, because some
FR residues directly contact the antigen or support conformation
of the CDR loops [4,5]. Therefore, humanized antibodies are usually
constructed by CDR grafting while retaining those mouse FRhumanized antibodies are generally less immunogenic in patients
than chimeric antibodies that are composed of mouse variable
domains and human constant domains; however, they may still
be immunogenic since the CDRs are not human [8,9]. Therefore,
to minimize the immunogenicity of humanized antibodies, only
the mouse CDR residues that inﬂuence antigen binding (i.e.,
speciﬁcity-determining residues, or SDRs) are retained, while those
that are not involved in antigen binding are replaced by
human counterparts [10–13]. SDR-grafted humanized antibodies
exhibit less immunogenic potential than CDR-grafted humanized
antibodies.
HBV is a worldwide public health problem that affects 240
million chronic carriers, who have a high risk of developing hepa-
tocellular carcinoma [14]. The HBV envelope contains three related
surface glycoproteins called the large (L), middle (M), and small (S)
proteins. These proteins are the product of a single open reading
frame that is divided into preS1, preS2, and S regions [15]. The S
protein is encoded by the S region; the M protein contains the
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and S antigens. The three antigens have been shown to elicit
virus-neutralizing antibodies [16–20]. In particular, the preS1
(amino acids 2–48, ayw subtype) of the L protein and the common
‘‘a’’ determinant of the S antigen have been shown to play an
essential role in viral infectivity [21–27]. Recently a cellular recep-
tor for the pre-S1 sequence was identiﬁed as sodium taurocholate
transporter (NTCP) [28], while heparin sulfate proteoglycan (HSPG)
was recognized as a binding partner for the ‘‘a’’ determinant [29].
For immunoprophylaxis of HBV infection, hepatitis B immune
globulin (HBIG) prepared from pooled human anti-HBsAg plasma
is administered to infants born of HBsAg-HBeAg-positive mothers,
to susceptible individuals with acute exposure to infectious HBV-
containing material, and to orthotopic liver transplant patients
with chronic HBV-related liver disease [30–32]. However, the cur-
rently available HBIG is not an ideal source of antibody due to its
limited availability and low speciﬁc activity. Virus-neutralizing
mAbs against the preS1 and S antigens would be an effective alter-
native for immunoprophylaxis of HBV infection.
We previously generated a murinemAb (KR127) that recognizes
amino acids 37–45 (NSNNPDWDF) of the preS1 of adr subtype,
corresponding to aa 26–34 of ayw subtype, and subsequently
constructed a humanized antibody (HzKR127) by CDR grafting.
HzKR127 retained the same epitope speciﬁcity and afﬁnity as
KR127 and exhibited HBV-neutralizing activity in chimpanzees
[33–35]. In addition, we determined the crystal structure of the
HzKR127 antigen-binding fragment (Fab) and its complex with
the epitope to understand the structural mechanisms of the anti-
gen–antibody interaction [36].
In the present study, based on the structural information, we
further humanized HzKR127 by SDR grafting and also improved
its afﬁnity by mutating two heavy-chain CDR residues. The
resulting humanized antibody (HzKR127-3.2) exhibited higher
HBV-neutralizing activity than KR127 and lower immunogenic
potential than HzKR127. The enhanced virus-neutralizing activity
was achieved by an increase in the association rate. This informa-
tion will be useful for the design and development of potent anti-
body therapeutics against HBV, and this advanced humanized
antibody may be a good candidate for immunoprophylaxis of
HBV infection.2. Materials and methods
2.1. Cell culture
HEK293T, ACHN, B16F1, and SCK-L1 [37] cells were grown in
DMEM (Invitrogen) supplemented with 10% FBS. CHO-DG44 cells
were grown in DMEM/F12 (Invitrogen) with supplements as
described previously [35]. HepaRG cells were cultured and
differentiated as previously described [24] and maintained after
seeding into 96-well plates in William’s E medium (Gibco Life
technologies) supplemented with 5% fetal calf serum, 2% DMSO,
5 mg/L insulin, 5  106 M hydrocortisone, 5 lg/l sodium selenite,
20000 UI/L penicillin, and 20 mg/L streptomycin. All cells were
cultured in 5% CO2 in a 37 C humidiﬁed incubator.2.2. Construction, expression, and puriﬁcation of humanized
antibodies
Humanized VH and VL genes were synthesized by GeneArt
(Germany) and sequentially subcloned into the EcoRI-ApaI and
HindIII-BsiWI sites, respectively, of pdCMV-dhfrC-cA10A3 contain-
ing human Cc1 and Cj. The resulting expression plasmids were
introduced into HEK293T cells using Lipofectamine (Invitrogen).
The culture supernatant was subjected to afﬁnity chromatographyon a protein A-sepharose column (Millipore), and the protein con-
centration was determined with a NanoDrop (Thermo Scientiﬁc)
based on the molar extinction coefﬁcient. The integrity of the puri-
ﬁed protein was analyzed by SDS–PAGE.
2.3. Afﬁnity determination
Competition ELISA was performed as described previously [38].
Brieﬂy, a solution containing 5–10 ng of each antibody and various
concentrations (1010–106 M) of GST-preS1 (amino acids 1–56) as
a competing antigen were preincubated at 37 C for 3 h. The mix-
tures were then added to each well, which had been coated with
100 ng of GST-preS1. Bound antibody was detected by indirect
ELISA.
For afﬁnity determination by Octet Red, anti-human Fc-coated
biosensor tips (ForteBio, 18-0015) were activated in PBS with
0.1% w/v bovine serum albumin (0.1% PBA) for 20 min by agitating
96-well microtiter plates (Greiner bio-one, 655209) at 1000 rpm
and then saturated with 2 lg/ml antibody for 10 min. This typi-
cally resulted in capture levels of 1 nm. GST-preS1 was prepared
as a 2-fold serial dilution (6.25, 12.5, 25, 50, and 100 nM) in 0.1%
PBA and separately incubated with the antibody bound on the tips.
Association and dissociation rates were measured for 15 and
30 min, respectively. All measurements were corrected for baseline
drift by subtracting a control sensor exposed to running buffer
only. Operating temperature was maintained at 30 C. Data were
analyzed using a 1:1 interaction model (ﬁtting global, Rmax
unlinked by sensor) with ForteBio data analysis software 7.0.
2.4. Western blot analysis
GST-preS1 (amino acids 1–56) and each of the alanine replace-
ment mutants of the preS1 (amino acids 37–47) were expressed in
Escherichia coli DH5a cells as described previously [38]. Protein
extracts were subjected to 12% SDS–PAGE and western blot analy-
sis with KR127 or humanized KR127 antibody (1 lg/ml), followed
by anti-mouse or human IgG (Fc-speciﬁc)–HRP conjugate (1:5000
v/v, Thermo Scientiﬁc).
2.5. Flow cytometric analysis
Cells were incubated with 1 lg of antibody in 100 ll of PBA for
60 min at 4 C. After washing three times with PBA, the cells were
incubated with a ﬂuorescein isothiocyanate–conjugated anti-hFc
antibody (BD Pharmingen) for 30 min at 4 C. Propidium iodide-
negative cells were analyzed for antibody binding using FACSCali-
bur (Becton Dickinson).
2.6. In vitro HBV infection and neutralization assays
In vitro HBV infection and neutralization assays were carried
out using differentiated HepaRG cells and adr or ayw subtype of
HBV particles. The ayw viral particles were produced by transient
transfection of HepG2 cells [39] with plasmid (pHBVEcoR1-) con-
taining an overlength HBV genome originally described in Gripon
et al. [40], and supernatants from the transfected cells were con-
centrated ﬁfty-fold by PEG precipitation as previously described
[23]. The genomic sequence of the ayw subtype corresponds to
the sequence (genbank accession number V01460.1) published
by Galibert et al. [41], corresponding to genotype D by online geno-
typing analysis [42]. The adr particles were produced and concen-
trated by the same procedures using the pHBV 5.2 [43] containing
the preS1 sequence [44] that was identiﬁed as genotype C by the
online genotyping analysis.
For in vitro HBV infection, HepaRG cells were seeded at a den-
sity of 6  104 cells per well (containing 100 ll of culture medium)
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(about 6  106 viral genomic equivalent). HBV infection was also
performed in the presence of 4% PEG 8000 and a ﬁve-fold diluted
inoculum. PEG was added during the infection process, which
allows a great enhancement of viral infectivity without compro-
mising the speciﬁcity of the infection process as previously
described [45]. To evaluate binding of antibody to the viral parti-
cles present in the HBV inocula, ELISA plates were coated with
either KR127 or HzKR127-3.2 (1 lg/ml) in a carbonate buffer over-
night at room temperature. After saturation with 5% fetal calf
serum for 2 h at room temperature, serially diluted HBV inocula
were added and incubated for 4 h at room temperature. The bound
viral particles were then detected with an anti-HBs antibody con-
jugated with peroxidase from a HBs detection kit (Bio-Rad).
For the neutralization assay, the adr or ayw viral particles (5 ll)
were preincubated with 5 ll of antibody at the indicated concen-
trations at room temperature for 30 min and then incubated with
cultured HepaRG cells covered with 100 ll of the culture medium
for 24 h in the absence or presence of 4% PEG 8000. The infected
cells were washed with the medium and further incubated for
10 days, with the medium changed every 2 days. On day 10 postin-
fection, the culture supernatant was diluted in order to remain in
the quantitative range of the assay and the HBsAg concentration
was determined with an ELISA kit (Bio-Rad).
3. Results
3.1. Construction of humanized antibody HzKR127-3 by SDR grafting
We previously constructed an anti-preS1 humanized antibody
(HzKR127) from the murine mAb KR127 by CDR grafting. In
HzKR127, the CDRs of mouse VH and VL were grafted into human
germline segments DP7-JH4 and DPK12-JK4, respectively, while
eleven FR residues in the mouse VH and ﬁve FR residues in the
mouse VL that were thought to inﬂuence the CDR loops or to
stabilize the structure of the variable regions were retained [35].
The amino acid sequences of the VH and VL of KR127 and
HzKR127 are shown in Fig. 1. In this study, we further humanized
HzKR127 by SDR grafting and increased its afﬁnity by site-directed
mutagenesis.A
B
Fig. 1. Amino acid sequences of VH (A) and VL (B) of murine antibody KR127 and huma
DPK12 are the human Ig VH and Vj germ-line segments, respectively. The dashes indicFor SDR grafting, mouse residues that are buried and/or not
involved in antigen binding are replaced by human counterparts,
based on the previously determined three-dimensional structure
of the antigen–antibody complex [36]. For the VH, nine mouse FR
residues (Val12, Ala28, Ser30, Ile48, Lys66, Ala67, Leu69, Ala78,
and Phe91) were replaced by human residues, while two mouse
FR3 residues (Ala71 and Lys73) that are involved in the interaction
with HCDR2 loop were retained. Ala71 is in hydrophobic interac-
tion with Ile51 and Pro53, and Lys 73 is in hydrogen bonding with
Gly54 (Fig. 2A). For the VL, three mouse FR residues (Leu3, Ser43,
and Lys45) were replaced by human residues, while two mouse
FR2 residues (Leu36 and Arg46) were retained. Leu36 forms a tight
interaction with Trp103 of VH in the bottom of the antigen-binding
pocket and is close to the Glu98 side chain of the HCDR3 loop
(Fig. 2B). Thus, mutation of Leu36 to Tyr is likely to disturb the con-
formation of the antigen-binding pocket and prohibit optimal
binding to the antigen. Residue Arg46 forms a salt bridge with
Asp97 in HCDR3, which stabilizes the conformation of HCDR3 in
the free structure (Fig. 3A). In addition to the FR residues, two
LCDR2 residues (Lys53 and Leu54) were replaced by human resi-
dues because they are not involved in antigen binding (Fig. 2C).
The designed humanized VH and VL sequences were synthe-
sized and combined with human Cc1 and Cj, respectively, to con-
struct expression plasmid pdCMV-dhfrC-HzKR127-3. This plasmid
DNA was introduced into HEK293T cells, and the resulting human-
ized antibody (HzKR127-3) was puriﬁed from the culture superna-
tant. Afﬁnity determination by competition ELISA indicated that
the afﬁnity of HzKR127-3 for GST-preS1 was slightly lower than
that of the original KR127 antibody (Supplemental Fig. S1). Afﬁnity
determination by Octet Red indicated that HzKR127-3 had approx-
imately 3-fold lower afﬁnity (KD) compared to KR127; this
decrease was due mostly to an increase in the dissociation rate
(Supplemental Fig. S2A and S2B and Table 1).
3.2. Afﬁnity maturation of HzKR127-3
In our previous structural study, a comparison of the structures
of free HzKR127 Fab and its complex with the preS1 epitope
revealed that the HCDR3 loop undergoes the most noticeable
conformational change between the free and complex structures,nized antibodies (HzKR127, HzKR127-3, HzKR127-3.1 and HzKR127-3.2). DP7 and
ate identical amino acid residues.
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Fig. 2. Crystal structure of the HzKR127 Fab–preS1 complex. (A) Interaction between the VH FR3 residue (Ala71H or Lys73H) and HCDR2 (H2) loop. (B) Interaction between
the VL FR2 residue (Leu36L) and Trp103H in FR4. (C) Location of the LCDR2 residues (Leu54L and Lys53L). (D) Location of Asn58H in HCDR2. The VH and VL are shown in blue
and in pink, respectively. The CDR loops and preS1 peptide are colored yellow and green, respectively. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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Fig. 3. Hydrogen bonds between the HCDR3 lid (yellow) and neighboring residues in the free (A) and preS1-bound (B) HzKR127 Fab. The residues involved in the hydrogen
bonds are labeled, and the hydrogen bonds are indicated as dotted lines. The preS1 peptide is shown in green. The light and heavy chains are colored pink and blue,
respectively. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Afﬁnity determination of murine and humanized antibodies using Octet Red.
Antibody name KD (M) Kon (1/Ms) Koff (1/s)
KR127 1.23  109 4.68  104 5.74  105
HzKR127-3 3.97  109 4.23  104 1.68  104
HzKR127-3.1 8.13  1010 5.08  104 4.13  105
HzKR127-3.2 4.93  1010 1.08  105 5.32  105
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shown in Fig. 3A, the Asp97 residue is not involved in a direct
interaction with the preS1 antigen; rather, it forms a salt bridgewith Arg46 in the light chain FR2, which stabilizes closing of the
HCDR3 lid in the free structure. However, upon antigen binding,
the HCDR3 loop lid is opened and an antigen-binding pocket is
thereby created, leading to tight locking in of the peptide
(Fig. 3B). Residue Asp97 is located at the apex of the HCDR3 lid
and undergoes the largest movement, with a 9.6 Å shift in the main
chain upon lid opening (Supplemental Fig. S3). Alanine mutation of
the Asp97 would disrupt the salt bridge, making the HCDR3 loop
more ﬂexible. This could facilitate the structural transition from
the closed to the open state, thus leading to an increase in afﬁnity.
We therefore substituted an alanine for Asp97 of HzKR127-3. The
resulting antibody (HzKR127-3.1) was transiently expressed in
HEK293T cells, puriﬁed, and subjected to afﬁnity determination
Table 2
Assessment of potential immunogenicity of humanized antibodies by T-cell epitope analysis. Prediction of HLA-DR binding sites by ProPred analysis (www.imtech.res.in/raghave/
proped/index.html).
Antibody HzKR127 HzKR127-3.2 HzKR127 HzKR127-3.2 HzKR127 HzKR127-3.2
Location HCDR2/FR3 FR2 in VL FR2/LCDR2
Peptide sequence YNGKFKGKA YAQKFQGRV WLLQKPGQS WLLQKPGQP IYLVSKLDS IYLVSNRDS
MHC Class II molecules that Bind to peptide DRB1_0801
DRB1_0802
DRB1_0804
DRB1_0806
DRB1_0813
DRB1_0817
DRB1_1307
DRB1_0305
DRB1_0309
DRB1_0401
DRB1_0426
DRB1_0802
DRB1_1101
DRB1_1114
DRB1_1120
DRB1_1128
DRB1_1302
DRB1_1305
DRB1_1307
DRB1_1323
DRB5_0101
DRB5_0105
DRB1_0301
DRB1_0305
DRB1_0306
DRB1_0307
DRB1_0308
DRB1_0309
DRB1_0311
DRB1_0801
DRB1_0802
DRB1_0804
DRB1_0806
DRB1_0813
DRB1_0817
DRB1_1101
DRB1_1102
DRB1_1104
DRB1_1106
DRB1_1107
DRB1_1114
DRB1_1120
DRB1_1121
DRB1_1128
DRB1_1301
DRB1_1302
DRB1_1304
DRB1_1305
DRB1_1307
DRB1_1311
DRB1_1321
DRB1_1322
DRB1_1323
DRB1_1327
DRB1_1328
DRB1_0402
DRB1_0404
DRB1_0405
DRB1_0408
DRB1_0410
DRB1_0423
DRB1_1102
DRB1_1121
DRB1_1322
DRB5_0101
Total number 7 0 15 0 33 10
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HzKR127-3.1 (8.13  1010 M) was 4.9-fold higher than that of
HzKR127-3 (3.97  109 M), and the increase in afﬁnity was
achieved mostly by a decrease in the dissociation rate (Supplemen-
tal Fig. S1 and S2C and Table 1).
In an attempt to further increase the afﬁnity of HzKR127-3.1,
Asn58 in HCDR2 of HzKR127-3.1 was mutated to alanine and sub-
jected to competition ELISA, which showed an increase in afﬁnity
(data not shown). This indicates that Asn58 is not optimal for anti-
gen binding. We speculated that the replacement of Asn58 by ala-
nine, which has a smaller side chain, would give the preS1 epitope
easier access to the antigen-binding pocket, which could result in a
faster association rate (Fig. 2D). Therefore, Asn58 was replaced by
the human counterpart (Ser58) as a ﬁrst choice. The resulting
humanized antibody (HzKR127-3.2) was transiently expressed,
puriﬁed, and subjected to afﬁnity determination. The afﬁnity of
HzKR127-3.2 (4.93  1010 M) was 1.6-fold higher than that of
HzKR127-3.1, and the increased afﬁnity was achieved mostly by
an increase in the association rate (Supplemental Fig. S1 and S2D
and Table 1).
3.3. Analysis of potential immunogenicity of HzKR127-3.2
The VH and VL sequences of HzKR127 and HzKR127-3.2 were
analyzed with ProPred [46] to identify potential T cell epitopes that
bind to MHC II molecules (HLA-DR). This is based on the fact that
the peptide–MHC II complexes are recognized by helper T cells
and trigger the activation and differentiation of helper T cells to
stimulate the immune response. As summarized in Table 2, poten-
tial T cell epitopes detected at the junction between HCDR2 andFR3 (HCDR2/FR3) or in the light chain FR2 of HzKR127 were elim-
inated in HzKR127-3.2, while those detected at the junction
between light chain FR2 and LCDR2 (FR2/LCDR2) were greatly
reduced.
3.4. Speciﬁcity of HzKR127-3.2
To conﬁrm the antigen-binding speciﬁcity of HzKR127-3.2, a
series of GST-preS1 (amino acids 1–56) proteins that individually
carry an alanine replacement mutation at each position in the
preS1 epitope were expressed in E. coli and subjected to western
blot analysis with KR127 or HzKR127-3.2. As shown in Fig. 4A,
HzKR127-3.2 exhibited the same epitope speciﬁcity as that of
KR127.
In addition, to determine whether HzKR127-3.2 does not
exhibit off-target activity, ﬂow cytometric analysis was performed.
To prepare preS1-expressing cells (293T-S1-L1) as a positive
control, preS1 (amino acids 37–47) was fused to the N-terminus
of the integral membrane protein L1 cell adhesion molecule
(L1CAM). The fusion protein was then transiently expressed in
HEK293T cells. HzKR127-3.2 bound to the surface of the
293T-S1-L1 cells but did not bind to preS1-negative cells such as
HEK293T, L1CAM-overexpressing human cholangiocarcinoma
(SCK-L1), human renal carcinoma (ACHN), mouse melanoma
(B16F1), and Chinese hamster ovary (CHO) cells (Fig. 4B).
3.5. Evaluation of HBV-neutralizing activity of HzKR127-3.2
Because HzKR127-3.2 exhibited higher afﬁnity for the preS1
antigen than KR127, we compared their virus-neutralizing
(kDa) 
35 
25 
KR127 
hzKR127-3.1 
GST-preS1 
hzKR127-3.2 
A 
ACHN 
293T 293T-S1-L1 SCK-L1 
B16F1 CHO 
B 
Fig. 4. Validation of epitope speciﬁcity (A) and off-target activity (B) of HzKR127-3.2. (A) GST-preS1 (amino acids 1–56) protein (WT) and a series of alanine replacement
mutants were expressed in E. coli and subjected to 12% SDS–PAGE (bottom) followed by western blot analysis with KR127, HzKR127-3.1, or HzKR127-3.2 (Top). The protein
band corresponding to the GST-preS1 is marked. (B) HzKR127-3.2 was subjected to ﬂow cytometric analysis using preS1-expressing HEK293T cells (293T-S1-L1) and preS1-
negative cells (HEK293T, SCK-L1, ACHN, B16F1, and CHO). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this
article.)
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conﬁrmed binding of the antibodies to the viral particles. As shown
in Fig. 5A, the antibodies bound to the ayw and adr particles in a
dose-dependent manner, and HzKR127-3.2 bound more efﬁciently
compared to KR127. Next, HepaRG cells were infected with either
the adr or ayw subtype of HBV particles, which had been preincu-
bated with different concentrations (0.2–200 lg/ml) of each anti-
body. The infected cells were then cultured for 10 days, and the
growth medium was changed every 2 days. On day 10 postinfec-
tion, HBsAg secretion by the infected cells was measured by ELISA.
As shown in Fig. 5B and C, the HBsAg secretion rate gradually
decreased with increasing antibody concentration, demonstrating
the speciﬁcity of the neutralization assay, and HzKR127-3.2 exhib-
ited enhanced virus-neutralizing activity against both adr and ayw
subtypes compared to KR127.
We also performed the HBV infection and neutralization assay
in the presence of 4% PEG 8000. The presence of PEG increases
the infectivity and thus allowed to use ﬁve-fold diluted inoculum
without compromising infectivity [45]. Because this assay has a
higher ratio of antibody molecules to viral particles compared to
the assay in the absence of PEG, it was expected to improve the
neutralization activity of the antibodies, although it is not under
physiological conditions. Indeed the infection level was highersince HBsAg production reached 100 ng/ml, and an almost com-
plete neutralization was observed with the highest antibody dose,
while HzKR127-3.2 neutralized the viral particles more efﬁciently
than KR127 (Supplemental Fig. S4).
4. Discussion
We had previously constructed the CDR-grafted humanized
antibody HzKR127; the epitope speciﬁcity and afﬁnity of HzKR127
are the same as those of the original murine mAb, KR127. HzKR127
virus-neutralizing activity was conﬁrmed in chimpanzees. Subse-
quently, the crystal structures of HzKR127 Fab and its complex
with the epitope revealed that HzKR127 exerts a lid-opening
mechanism for antigen binding, one of the largest conformational
changes in antigen–antibody recognition. In the present study,
we successfully optimized HzKR127 through SDR grafting and
afﬁnity maturation by rational design based on the antigen–anti-
body complex structure. A total of 15 (12 in FR, one in HCDR2,
and two in LCDR2) mouse residues in HzKR127 were replaced by
human residues, and Asp97 in HCDR3 was replaced by alanine.
The resulting humanized antibody (HzKR127-3.2) exhibited
2.5-fold higher afﬁnity for the preS1 antigen and enhanced virus-
neutralizing activity against both adr and ayw subtypes of HBV
Fig. 5. In vitro HBV binding (A) and neutralization (B and C) assays of HzKR127-3.2
against ayw or adr subtypes of HBV.
J.H. Kim et al. / FEBS Letters 589 (2015) 193–200 199compared to KR127. Moreover, it retained the same epitope
speciﬁcity as that of KR127 and did not show any off-target activ-
ity, as assessed by ﬂow cytometric analysis. In addition, T epitope
analysis suggested that HzKR127-3.2 may be less immunogenic in
humans than HzKR127. Considering that HzKR127 exhibited virus-
neutralizing activity in chimpanzees, HzKR127-3.2 might exhibit
higher in vivo virus-neutralizing activity than HzKR127 and thus
may be more effective in the immunoprophylaxis of HBV infection.
HzKR127-3.2 may be particularly useful for repeated administra-
tion to humans because of its minimized immunogenic potential.
KR127 and HzKR127-3.2 target amino acids 37–45 from the L
protein of adr subtype, corresponding to amino acids 26–34 of
ayw subtype. This epitope lies in preS1 region of the L protein
which is involved in HBV infectivity, since the target of the peptide
(amino acids 2–47, ayw subtype) was identiﬁed as NTCP and
shown to be a functional receptor for HBV entry [28]. Therefore,
our antibodies target a region crucial for HBV infectivity and thus
were expected to block entry. However, Bremer et al. reported that
antibodies against preS1 (1–21) of ayw subtypes reacted well with
non-myristoylated preS1 peptides but only weakly with myristoy-
lated preS1 peptides and did not neutralize the infectivity of HBV,
whereas antibodies to neighboring sequences neutralized very
well [47]. The data suggest that antibodies to preS1 (22–47) of
ayw subtypes are likely to bind well to HBV and neutralize viralinfectivity. Indeed, we observed that HzKR127-3.2 recognizing
preS1 (37–45) of adr subtypes bound to the viral particles of both
ayw and adr subtypes and neutralized them efﬁciently. Analysis of
antigen-antibody interaction of HzKR127-3.2 indicated that seven
residues in the epitope sequence, except Ser38 and Asn39, are
essential for antibody binding (Fig. 4). Among the essential resi-
dues, ﬁve residues (Asn37, Pro41, Asp42, Trp43, and Asp44) are
highly conserved among genotypes [28], while the other two resi-
dues (Asn40 and Phe45) are infrequently changed to serine and
leucine or histidine, respectively in some genotypes. Neutralization
efﬁciency of HzKR127-3.2 against these genotypes remains to be
determined.
Regarding the correlation between kinetic parameters and
virus-neutralizing potency, studies with mAbs against respiratory
syncytial virus (RSV) F protein have shown that a direct relation-
ship exists between the association rate and RSV-neutralizing
activity [48–50], while studies with other viral pathogens, such
as human immunodeﬁciency virus or rotavirus, have shown that
virus-neutralizing activity can be determined predominantly by
the dissociation rate [51,52]. In case of HBV-neutralizing antibody,
a recent study showed no correlation between the afﬁnity of anti-S
monoclonal antibodies and their ability to neutralize HBV infection
[53]. In this study, HzKR127-3.2 exhibited 2.5-fold higher afﬁnity
for the preS1 and enhanced in vitro virus-neutralizing activity
against both adr and ayw subtypes of HBV compared to KR127,
while the association rate was 2.3-fold faster and the dissociation
rate was slightly slower. These data indicate that the enhanced
virus-neutralizing activity was achieved by an increased associa-
tion rate, which suggests that the association rate of anti-preS1
antibodies may play a predominant role in HBV neutralization.
To the best of our knowledge, this is the ﬁrst study to show a direct
relationship between the association rate and neutralizing potency
in antibody-mediated HBV neutralization. Our ﬁndings may pro-
vide insights that will help to facilitate the engineering of potent
antibody therapeutics for HBV immunoprophylaxis.
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